Accretion of issuance costs on Series A Convertible Redeemable Preferred stock

No definition available.

Name:	acer_AccretionOfIssuanceCostsOnSeriesAConvertibleRedeemablePreferredStock
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Agreement entered month and year.

+ References

No definition available.

+ Details

Name:	acer_AgreementEnteredMonthAndYear
Namespace Prefix:	acer_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

- Definition

CARES act of 2020 aid loan amount.

+ References

No definition available.

+ Details

Name:	acer_CARESActOf2020AidLoanAmount
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Commitments and contingencies.

+ References

No definition available.

+ Details

Name:	acer_CommitmentsAndContingenciesLineItems
Namespace Prefix:	acer_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Development and commercial launch costs.

+ References

No definition available.

+ Details

Name:	acer_DevelopmentAndCommercialLaunchCosts
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development payments subject to new drug application.

+ References

No definition available.

+ Details

Name:	acer_DevelopmentPaymentsSubjectToNewDrugApplication
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Guarantee for substantive review food and drug application.

+ References

No definition available.

+ Details

Name:	acer_GuaranteeForSubstantiveReviewFoodAndDrugApplication
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payment to be received.

+ References

No definition available.

+ Details

Name:	acer_MilestonePaymentToBeReceived
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Minimum percentage of loan proceeds used to cover payroll costs eligible for loan forgiven.

+ References

No definition available.

+ Details

Name:	acer_MinimumPercentageOfLoanProceedsUsedToCoverPayrollCostsEligibleForLoanForgiven
Namespace Prefix:	acer_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Net profit split ratio based on territory.

+ References

No definition available.

+ Details

Name:	acer_NetProfitSplitRatioBasedOnTerritory
Namespace Prefix:	acer_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of patent applications.

+ References

No definition available.

+ Details

Name:	acer_NumberOfPatentApplications
Namespace Prefix:	acer_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment of settlement plus legal fees and costs in excess of retention (deductible) amount.

+ References

No definition available.

+ Details

Name:	acer_PaymentOfSettlementPlusLegalFeesAndCostsInExcessOfRetentionDeductibleAmount
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of royalty revenue received.

+ References

No definition available.

+ Details

Name:	acer_PercentageOfRoyaltyRevenueReceived
Namespace Prefix:	acer_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential proceeds from development payments subject to new drug application.

+ References

No definition available.

+ Details

Name:	acer_PotentialProceedsFromDevelopmentPaymentsSubjectToNewDrugApplication
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Proceeds from first tranche of development payments subject to new drug application.

+ References

No definition available.

+ Details

Name:	acer_ProceedsFromFirstTrancheOfDevelopmentPaymentsSubjectToNewDrugApplication
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Proceeds from second tranche of development payments subject to new drug application.

+ References

No definition available.

+ Details

Name:	acer_ProceedsFromSecondTrancheOfDevelopmentPaymentsSubjectToNewDrugApplication
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Reimbursement Payment.

+ References

No definition available.

+ Details

Name:	acer_ReimbursementPayment
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Repayment of outstanding balance of prior loan and interest.

+ References

No definition available.

+ Details

Name:	acer_RepaymentOfOutstandingBalanceOfPriorLoanPlusInterest
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Second tranche of development payment, expiry date.

+ References

No definition available.

+ Details

Name:	acer_SecondTrancheOfDevelopmentPaymentExpiryDate
Namespace Prefix:	acer_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront non-refundable payment received.

+ References

No definition available.

+ Details

Name:	acer_UpfrontNonRefundablePaymentReceived
Namespace Prefix:	acer_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

+ Details

Name:	us-gaap_DebtInstrumentDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69C
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

+ Details

Name:	us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

+ Details

Name:	us-gaap_GainsLossesOnExtinguishmentOfDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of loss contingency liability.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of current assets classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

+ Details

Name:	us-gaap_OtherAssetsCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_OtherLiabilitiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=acer_SecuritiesClassActionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=acer_StockholdersDerivativeActionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=acer_PaycheckProtectionProgramLoanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LineOfCreditFacilityAxis=acer_JPMorganChaseBankNAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=acer_PromissoryNoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=acer_AssistancePubliqueHopitauxDeParisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=acer_ReliefTherapeuticsHoldingAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=acer_CollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=acer_FirstDevelopmentPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=acer_SecondDevelopmentPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=acer_WaiverAndAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Details)								1 Months Ended		3 Months Ended	12 Months Ended
	Jan. 14, 2022 USD ($)	Oct. 12, 2021 USD ($)	Mar. 19, 2021 USD ($)	Jan. 25, 2021 USD ($)	Jan. 21, 2021 USD ($)	Jun. 05, 2020	Apr. 11, 2020 USD ($)	Sep. 30, 2018 Patent	Aug. 31, 2016	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Oct. 04, 2021 USD ($)	Dec. 31, 2020 USD ($)
Commitments And Contingencies [Line Items]
Reimbursement payment			$ 14,000,000.0
Minimum percentage of loan proceeds used to cover payroll costs eligible for loan forgiven						60.00%	75.00%
Gain on extinguishment of debt											$ 568,909
Other current liabilities											9,450,085		$ 692,336
Other current assets											9,283,625		$ 168,826
Pending Litigation \| The Securities Class Action
Commitments And Contingencies [Line Items]
Proposed settlement as a loss in accrued expenses											8,400,000
Other current liabilities											900,000
Other current assets											$ 900,000
Pending Litigation \| Stockholders Derivative Action
Commitments And Contingencies [Line Items]
Payment of settlement plus legal fees and costs in excess of retention (deductible) amount					$ 500,000
PPP Loan
Commitments And Contingencies [Line Items]
Debt instrument, description											On June 5, 2020, the Payroll Protection Flexibility Act of 2020 was signed into law, adjusting certain terms of the loans issued under the PPP, including extending the initial deferral period from six to up to ten months, reducing from 75% to 60% the portion of loan proceeds required to be used to cover payroll costs, and allowing borrowers to elect a 24-week rather than an eight-week period related to employment and compensation provisions.
Gain on extinguishment of debt											$ 600,000
PPP Loan \| Other Current Liabilities
Commitments And Contingencies [Line Items]
CARES act of 2020 aid loan amount							$ 400,000
PPP Loan \| Other Non-current Liabilities
Commitments And Contingencies [Line Items]
CARES act of 2020 aid loan amount							200,000
PPP Loan \| JPMorgan Chase Bank, N.A
Commitments And Contingencies [Line Items]
CARES act of 2020 aid loan amount							$ 600,000
Promissory Note \| JPMorgan Chase Bank, N.A
Commitments And Contingencies [Line Items]
Debt instrument, term							2 years
Debt instrument, interest rate							1.00%
Assistance Publique - Hopitaux de Paris ("AP-HP") \| License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date								2018-09	2016-08
Number of patent applications \| Patent								3
Relief Therapeutics Holding AG \| Collaboration Agreement
Commitments And Contingencies [Line Items]
Upfront non-refundable payment received				$ 1,000,000.0
Cash payment received				10,000,000.0
Reimbursement payment			14,000,000.0	14,000,000.0
Repayment of outstanding balance of prior loan and interest			4,000,000.0	4,000,000.0
Development and commercial launch costs			$ 20,000,000.0
Potential proceeds from development payments subject to new drug application												$ 10,000,000.0
Guarantee for substantive review food and drug application				$ 0
Net profit split ratio based on territory			60.00%	60.00%
Percentage of royalty revenue received				15.00%
Milestone payment to be received			$ 6,000,000.0	$ 6,000,000.0
Proceeds from first tranche of development payments subject to new drug application		$ 5,000,000.0
Relief Therapeutics Holding AG \| Collaboration Agreement \| First Development Payment
Commitments And Contingencies [Line Items]
Development payments subject new drug application										$ 10,000,000.0
Relief Therapeutics Holding AG \| Collaboration Agreement \| Second Development Payment
Commitments And Contingencies [Line Items]
Potential proceeds from development payments subject to new drug application												$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application		5,000,000.0
Relief Therapeutics Holding AG \| Collaboration Agreement \| Maximum
Commitments And Contingencies [Line Items]
Development and commercial launch costs				$ 20,000,000.0
Relief Therapeutics Holding AG \| Collaboration Agreement \| Secured Loan
Commitments And Contingencies [Line Items]
Debt instrument, term				12 months
Debt instrument, principal amount				$ 4,000,000.0
Debt instrument, interest rate				6.00%
Relief Therapeutics Holding AG \| Waiver and Agreement
Commitments And Contingencies [Line Items]
Proceeds from second tranche of development payments subject to new drug application		5,000,000.0
Relief Therapeutics Holding AG \| Waiver and Agreement \| Second Development Payment
Commitments And Contingencies [Line Items]
Proceeds from first tranche of development payments subject to new drug application	$ 5,000,000.0	5,000,000.0
Proceeds from second tranche of development payments subject to new drug application		$ 5,000,000.0
Relief Therapeutics Holding AG \| Waiver and Agreement \| Subsequent Event
Commitments And Contingencies [Line Items]
Second tranche of development payment, expiry date	Jan. 14, 2022
Relief Therapeutics Holding AG \| Waiver and Agreement \| Subsequent Event \| Second Development Payment
Commitments And Contingencies [Line Items]
Proceeds from second tranche of development payments subject to new drug application	$ 5,000,000.0
Second tranche of development payment, expiry date	Jan. 14, 2022